Plasma GABA predicts acute response to divalproex in mania.

Journal Article (Clinical Trial;Journal Article;Multicenter Study)

Bipolar I, manic phase inpatients were treated with divalproex sodium, lithium, or placebo in a previously reported parallel group multicenter, double-blind, randomized, controlled acute phase treatment trial. Plasma concentrations of gamma aminobutyric acid (GABA) were measured before and after treatment. Higher pretreatment plasma GABA levels were significantly (p = .04) related to a better clinical response to divalproex (n = 19). Pretreatment plasma GABA levels did not correlate with response to either lithium (n = 13) or placebo (n = 31). Following treatment with divalproex sodium, plasma GABA levels decreased significantly (p < .05), compared to placebo. Pretreatment plasma GABA levels were not related to overall severity of manic symptoms. Plasma GABA may predict response to pharmacologic agents acting on the GABA system.

Full Text

Duke Authors

Cited Authors

  • Petty, F; Rush, AJ; Davis, JM; Calabrese, JR; Kimmel, SE; Kramer, GL; Small, JG; Miller, MJ; Swann, AE; Orsulak, PJ; Blake, ME; Bowden, CL

Published Date

  • February 15, 1996

Published In

Volume / Issue

  • 39 / 4

Start / End Page

  • 278 - 284

PubMed ID

  • 8645774

International Standard Serial Number (ISSN)

  • 0006-3223

Digital Object Identifier (DOI)

  • 10.1016/0006-3223(95)00141-7


  • eng

Conference Location

  • United States